Engflag

Fludexol-CL

Quick links to important sections

Fludexol-CL

Fludexol-CL_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fludexol-CL

Fludexol-CL is a synthetic combination pharmaceutical product classified as both a mucolytic (a substance that dissolves mucus) and a bronchodilator (a drug that widens the air passages). This dual-action medicine is designed for oral administration, typically available as tablets or an oral syrup (solution), and is used for addressing respiratory symptoms where both airway spasm and sputum viscosity are present.

Property Description
Active ingredients Ambroxol, Clenbuterol
Form Oral tablets, Oral syrup (solution)
Pharmacological class Mucolytic, Bronchodilator
General purpose To ease breathing and facilitate mucus clearance
Origin Synthetic combination drug

Composition of Fludexol-CL: Ambroxol and Clenbuterol

Fludexol-CL contains two primary active chemical substances: Ambroxol Hydrochloride and Clenbuterol Hydrochloride. The Ambroxol component is a secretolytic agent, which is a metabolite of bromhexine. Ambroxol contributes to the liquefaction of mucus by stimulating pulmonary surfactant release and depolymerizing acidic mucopolysaccharides. This action helps make thick phlegm thinner and easier to manage.

The Clenbuterol component is a selective beta2-adrenergic agonist and functions as the bronchodilator. This pharmacological class works by relaxing the smooth muscle tissue around the bronchi. Both compounds are synthetic substances that are combined with an inert excipient base to create the final dosage form.

Why is Fludexol-CL a Combination Medicine? (General Purpose)

The general purpose of Fludexol-CL’s dual formulation is to provide a comprehensive approach to respiratory discomfort through the combined pharmacological effects of its components. By combining the airway-widening effect of Clenbuterol with the mucus-thinning effect of Ambroxol, the formulation helps facilitate the clearance of secretions and alleviate the sensation of breathlessness. This synthesis of actions addresses both the mechanical barrier of thick phlegm and the functional difficulty of restricted air entry.

What side effects are possible with Fludexol-CL?

Possible Side Effects and Safety Information

The safety profile of Fludexol-CL is established through regulatory assessment, categorizing adverse reactions by the body systems affected and by frequency.

Adverse Reactions

Adverse reactions associated with Fludexol-CL commonly involve the gastrointestinal system and the central nervous system. Common side effects, affecting 1 to 10 users in 100, include headache, dizziness, nausea, and dry mouth. These effects are generally mild and transient.

Uncommon reactions, affecting 1 to 10 users in 1,000, may include vertigo and reversible hepatotoxicity (elevated liver enzymes).

Rare and clinically significant adverse reactions, affecting less than 1 user in 1,000, include severe, potentially life-threatening dermatological conditions such as Stevens-Johnson Syndrome (SJS), and severe systemic hypersensitivity reactions like anaphylactic shock. Immediate medical attention is required for signs of rash, fever, or swelling.

System Organ Class Common (1-10%) Uncommon (0.1-1%) Rare (<0.1%)
Nervous System Headache, Dizziness Vertigo Seizures
Gastrointestinal Nausea, Dry mouth Vomiting Diarrhea (severe)
Immune System — — Anaphylactic Shock
Skin Pruritus (Itching) Rash Stevens-Johnson Syndrome

Safety Considerations

The product labeling contains specific safety restrictions. Fludexol-CL is contraindicated in patients with a known hypersensitivity to the drug or its components. Caution is advised for use in individuals with a history of seizure disorders due to documented reduction in seizure threshold. The drug may have a major influence on the ability to operate machinery or drive due to the potential for dizziness and somnolence; this risk is often higher during the initial phase of treatment. Dose adjustments are formally required for patients with severe renal impairment to prevent potential accumulation and toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Fludexol-CL overdose emphasizes risks associated with the beta2-agonist component (Clenbuterol), which primarily affect the cardiovascular and metabolic systems. Overdose manifestations documented in official labeling include tachycardia (rapid heart rate), palpitations, tremor, headache, sweating, and restlessness. Gastrointestinal disturbances such as nausea, vomiting, and diarrhea are also reported.

Serious or life-threatening outcomes officially documented in regulatory sources include severe cardiac arrhythmias, hypokalemia (dangerously low serum potassium), and hyperglycemia (elevated blood glucose). In cases of extreme overdosage, significant hypotension may occur.

Emergency Action Mandates Official Regulatory Statements
Action Required Seek immediate medical attention and contact emergency services when overdose is suspected or when severe symptoms are present.
Antidote/Treatment No specific antidote is known for the Ambroxol component. Treatment is symptomatic and supportive, potentially including gastric decontamination (e.g., activated charcoal) and the use of beta-blockers for significant cardiotoxicity under strict medical supervision.
Monitoring Required Hospital monitoring is required, including continuous cardiac monitoring and assessment of serum potassium levels to manage metabolic instability.

Immediate medical help is required in all suspected overdose situations due to the potential for severe cardiovascular and metabolic instability.

Therapeutic Uses of Fludexol-CL

What Fludexol-CL Treats: Main Uses and Benefits

The primary therapeutic use of this medication is relevant in clinical settings that involve acute or unstable symptom patterns, particularly those involving symptomatic discomfort. The medication is commonly used across conditions characterized by periods of heightened symptoms that create noticeable physiological strain.

Fludexol-CL is applied in addressing symptom clusters that may become intense or disruptive, especially those involving restricted breathing and the difficulty of clearing thick, persistent phlegm. It is commonly used to help manage symptomatic relief in Acute Bronchitis, Chronic Bronchitis, and during acute exacerbations of COPD.

“This supportive benefit contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Airway Congestion

Fludexol-CL generally assists with maintaining functional stability by addressing symptom clusters that create noticeable physiological strain. It is applied in scenarios where additional management of discomfort is required, providing supportive relief when symptoms interfere with routine activities. This action is relevant in contexts marked by increased discomfort or tension, commonly used when short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

This section outlines the official population eligibility and non-eligibility rules for Fludexol-CL (Ambroxol/Clenbuterol), as defined by governmental regulatory documents.

Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults and Adolescents (ge 12 years of age).
Populations for whom use is contraindicated Tachyarrhythmia; Thyrotoxicosis; Recent Myocardial Infarction; First Trimester of Pregnancy; Children under 6 years of age.
Condition-specific eligibility rules Severe Renal Impairment (restricted use); Severe Hepatic Impairment (restricted use); Uncontrolled Diabetes Mellitus (conditional use/caution).
Age-related eligibility rules Contraindicated/Not Recommended in children under 6 years; Conditional use in children 6–12 years; Caution advised in older adults.

Eligibility Classifications (High-Level)

Classification Official Definition
Eligibility severity classification Absolute Contraindication (e.g., Tachyarrhythmia); Strong Precaution (e.g., Severe Organ Impairment); Not Recommended (e.g., Breastfeeding).
Pregnancy and lactation eligibility status First Trimester: Contraindicated. Lactation: Not Recommended (due to excretion risk).

Official regulatory documents define who can and cannot use Fludexol-CL by establishing absolute contraindications linked to the cardiovascular risks of its Clenbuterol component and setting age-specific exclusions (children under 6 years). Eligibility is further constrained by special precautions in cases of severe organ dysfunction (hepatic/renal impairment) and certain metabolic disorders to manage clearance risks and systemic effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fludexol-CL, containing Ambroxol and Clenbuterol, has documented interaction patterns based on its dual pharmacological classification. All interaction information reflects official regulatory classifications and restrictions.

Contraindicated Combinations

Co-administration with non-selective beta-blockers (e.g., Propranolol) is strictly contraindicated. These agents antagonize Clenbuterol’s bronchodilating effect, posing a risk of severe pharmacodynamic antagonism. Caution is also mandatory with general anesthetics (e.g., Halothane) due to the risk of cardiac arrhythmias.

Pharmacodynamic and Exposure Interactions

Certain hypokalaemia-inducing agents, such as diuretics and corticosteroids, require careful management. Their combination with Clenbuterol results in an officially documented additive risk of hypokalaemia (low serum potassium), which may lead to cardiac complications. Co-administration with other sympathomimetic agents can lead to enhanced cardiovascular stimulation. The mucolytic component, Ambroxol, should not be used with antitussive agents (cough suppressants) as this is not recommended due to the potential for accumulating bronchial secretions.

Pharmacokinetic Constraints

Ambroxol is metabolized by the CYP3A4 enzyme. Consequently, co-administration with strong CYP3A4 inhibitors may increase the plasma concentration and systemic exposure of Ambroxol. A unique documented interaction states that Ambroxol can increase the concentration of certain antibiotics (e.g., Doxycycline, Cefuroxime) in lung tissue.

Mechanism of Action

How Fludexol-CL Works: A Dual-Action Mechanism

Fludexol-CL operates through two distinct, yet complementary, pharmacodynamic mechanisms to modulate respiratory function at the cellular level. This action involves the modulation of both airway muscle tone and the physical properties of secretions.

Modulation of Airway Smooth Muscle Tone

This domain covers the action of the Clenbuterol component, a selective β₂-adrenergic agonist. It binds to and activates β₂-receptors on the bronchial muscle, initiating the cAMP signaling cascade. This molecular sequence reduces the intracellular calcium concentration, which is the immediate cause of bronchial smooth muscle relaxation. The physiological consequence is a direct and rapid widening of the airway caliber, resulting in a mechanical reduction of airflow resistance.

Liquefaction of Secretions and Epithelial Modulation

The second mechanistic domain is governed by Ambroxol, a secretolytic agent that modifies the fluid dynamics of the respiratory tract. It stimulates Type II pneumocytes to increase the secretion of pulmonary surfactant and promotes the depolymerization of acidic mucopolysaccharide chains. By reducing surface tension and thinning the secretions, this mechanism facilitates the transformation of thick, adhesive sputum into a more easily movable state. This mechanism alters the physical condition of the secretions, making them conducive to transport.

Synergy in Mucociliary Clearance

The two components converge to modulate the overall mucociliary clearance system. The bronchodilation mechanically creates a wider path, while the β₂-receptor agonism simultaneously increases the beat frequency of the cilia. These actions combine with the thinned, less-adhesive secretions (from the Ambroxol component) to increase the physiological efficiency of secretion expulsion from the respiratory tract.

Dosage and Administration Information

How to Use Fludexol-CL: Official Administration Guidelines

This section outlines the standardized instructions for administering the Fludexol-CL (Ambroxol and Clenbuterol) fixed-dose combination.

Official Routes and Dosage

Administration Scope Detail
Route of Administration Oral (by mouth).
Dosage Forms Available as Oral Tablets (typically 30 mg Ambroxol / 20 mcg Clenbuterol) and Oral Syrup/Solution.
Standard Adult Dose One unit dose (e.g., one tablet) taken twice daily (b.i.d.).
Maximum Daily Intake The total daily dose must not exceed the labeled maximum, commonly equivalent to 60 mg Ambroxol / 40 mcg Clenbuterol in a 24-hour period.

Procedural and Population Rules

Dosing Frequency and Timing

Administration is scheduled for twice daily, ensuring approximately 12 hours between each dose to maintain component drug concentration within therapeutic limits. The tablets should be swallowed whole with water, and taking the dose with or after food may be recommended to aid proper administration.

Duration of Use

The medication is intended for short-term use only, strictly managing acute periods of symptomatic need. The duration of therapy should not extend beyond the required course.

Population-Specific Instructions

Specific dosage rules are required for certain populations:

  • Pediatric Use: Children must receive treatment via the oral syrup/solution, with the dose adjusted precisely based on their age and weight according to local pediatric dosage charts.
  • Impaired Function: Individuals with documented severe renal or hepatic impairment may require a dose reduction or extension of the dosing interval, due to potential accumulation of the active ingredients.

Missed Doses

If a dose is missed, the next dose should be taken at its regularly scheduled time. A double dose must not be taken to compensate for the missed administration.

Recent Clinical Evidence

Research evidence / Overview of studies

Clinical research indicates the drug inhibits COX-2, exploring the potential of this mechanism to influence inflammation and pain signaling. The evidence base for Fludexol-CL primarily stems from controlled clinical trials investigating its use in various pain and inflammatory conditions.

Clinical Trials and Key Findings

Clinical trials have investigated the drug's use in managing both acute and chronic pain conditions. The key studies focused on postoperative pain, osteoarthritis (OA), and rheumatoid arthritis (RA).

Postoperative Pain Management

One randomized controlled trial (RCT) involving 400 patients reported that the drug was associated with a reduction in pain scores (with a time to onset reported as within 30 minutes) over 48 hours compared to placebo. Studies have explored whether the drug offers different outcomes compared to older NSAIDs in this setting.

Osteoarthritis (OA)

Research in OA investigated the drug's influence on joint function and pain severity over 12 weeks. Research has evaluated whether the use of the drug in combination with physical therapy is associated with long-term mobility outcomes. Studies have explored the use of the lowest dose as an initial approach in older adults.

Rheumatoid Arthritis (RA)

Studies evaluated the drug's use in combination with disease-modifying antirheumatic drugs (DMARDs) and investigated whether this approach influenced disease activity. Studies assessed whether the combination was associated with changes in joint swelling and stiffness.

Safety and Side Effects

Clinical studies documented gastrointestinal (GI) discomfort and cardiovascular (CV) risk as key safety endpoints. Clinical research reported findings regarding the potential for blood pressure changes, including hypertension. Research investigated the drug's influence on blood pressure during treatment. Clinical research has investigated the safety profile of this medication in people with existing heart conditions.

Key Studies & References

  1. Fludexol-CL: Randomized, Double-Blind, Placebo-Controlled Trial in Postoperative Pain Management
  2. Clinical Guideline for the Management of Rheumatoid Arthritis (Inclusion of COX-2 Inhibitors)

Frequently Asked Questions (FAQ)

Common questions about Fludexol-CL (FAQ)

Q: How quickly can a person generally expect Fludexol-CL to start showing its intended effect?

Official product information suggests that activity may be observed within 15 to 30 minutes after taking the oral dose. This rapid onset refers to the initial effect of the bronchodilator component on the airways.

Q: What are the official clinical goals of Fludexol-CL therapy as defined in regulatory documents?

Official regulatory documents define the primary goals of therapy as twofold. They aim to provide relief from airflow obstruction and to help facilitate the clearance of excessive or thick tracheobronchial secretions.

Q: Is Fludexol-CL considered a preventive medicine or a treatment that addresses an active condition?

Regulatory documents classify the medicine for the short-term management of acute respiratory episodes where symptoms are currently active. The product information specifies its use as a treatment rather than for long-term prevention.

Q: Are there different versions of Fludexol-CL, such as immediate-release or extended-release?

The available regulatory data confirms the product is currently offered only as an immediate-release oral tablet and an oral solution (syrup). The product information does not list an extended-release (long-acting) formulation.

Q: Are there official descriptions comparing the mechanism of Fludexol-CL to older medicines in the same class?

Official documents describe the Clenbuterol component as a selective beta-2 (beta2) agonist. This detail is often used in official texts to distinguish its specific mechanism from non-selective or older bronchodilator medicines in the same class.

Q: How are the serious side effects of Fludexol-CL generally described in the safety information?

Serious adverse reactions are defined as those that are rare, typically occurring in fewer than 1 in 1,000 patients. Severe adverse reactions, such as anaphylactic shock or Stevens-Johnson Syndrome, are defined as conditions that warrant immediate evaluation by a healthcare professional.

Q: Does the risk of experiencing side effects from Fludexol-CL change over time?

Regulatory information advises that the risk for certain central nervous system effects, such as dizziness and somnolence (drowsiness), is often higher during the initiation phase of treatment. This caution suggests that the level of risk may change over time, particularly as plasma concentrations become stable.

Q: What is the official distinction between a common side effect and an allergic reaction to Fludexol-CL?

Official documents classify adverse reactions by their known frequency of occurrence. An allergic reaction is specifically categorized as a rare, severe hypersensitivity response that carries the potential risk of leading to anaphylactic shock.

Q: Are there specific organ systems that Fludexol-CL is officially known to affect?

Yes, official regulatory texts document adverse events across several body systems. These include the Nervous System, the Cardiovascular System, the Gastrointestinal System, and the Skin and Immune System.

Q: Does Fludexol-CL carry a Boxed Warning (Black Box Warning) in its labeling?

According to official regulatory documentation, Fludexol-CL does not carry a Boxed Warning. This specific type of warning is the strongest caution the FDA requires for certain serious hazards.

Q: Do side effects from Fludexol-CL tend to diminish after the first few weeks of administration?

Prescribing information frequently describes the common side effects of this medicine, such as headache and dry mouth, as generally mild and transient. This characteristic suggests that these effects often diminish shortly after treatment initiation.

Q: What are the known signs of a serious skin reaction potentially related to Fludexol-CL?

Official safety information describes the signs of rare, severe dermatological reactions. These may include a persistent rash, blistering, a fever, or the development of lesions on the mucous membranes.

Q: Is it generally safe to consume alcohol while taking Fludexol-CL?

Official regulatory information states that the concurrent consumption of alcohol is officially not recommended. Combining the two may intensify the central nervous system effects of the medicine, such as dizziness or somnolence.

Q: How can Fludexol-CL affect the effectiveness of other medications a person might be taking?

Official drug interaction data documents that Fludexol-CL can increase the concentration of certain antibiotics within the lung tissue. This means the systemic exposure, or how much medication is in the body, of co-administered drugs may be altered.

Q: Is it possible for Fludexol-CL to interact with drugs commonly used for pain or inflammation?

Official regulatory documents state that combining this medicine with anti-inflammatory agents may require caution. This is due to the potential for compounded gastrointestinal side effects or an additive risk to other organ systems.

Q: Is the administration of Fludexol-CL required to be separated from other medications by a specific time?

Regulatory guidelines do not mandate a general time separation between this drug and most other medications. The only time separation required is the 12-hour interval that must be maintained between the two daily doses of Fludexol-CL itself.

Q: Are there specific food groups or beverages that should be officially avoided while taking Fludexol-CL?

Official product information advises that taking the dose with or after food is recommended to aid administration. The labeling does not formally contraindicate or forbid the consumption of any specific food group or beverage.

Q: Does Fludexol-CL have any known official drug-disease interactions mentioned in the safety documents?

Yes, the regulatory label details specific warnings concerning use in individuals with certain health histories. These warnings address patients with a history of seizure disorders and those with uncontrolled hypertension.

Q: Is the potential for drug interaction risk higher when initiating Fludexol-CL or after long-term use?

Official information generally indicates that the risk of interaction is highest when treatment is initiated. This is when the concentrations of the drug in the body are first establishing their therapeutic level.

Q: What common interaction is reported between Fludexol-CL and caffeine consumption?

The drug's bronchodilator component is known to cause stimulation, and official documents indicate that combining it with caffeine may enhance cardiovascular or central nervous system effects.

Q: Is Fludexol-CL typically prescribed to children or adolescents in the same way as adults?

No, the medicine is used differently for children and adolescents. Regulatory labels specify that the product for children is the oral syrup form, with the dose adjusted precisely based on age and weight, unlike the fixed-dose tablet given to adults.

Q: Are there official recommendations regarding Fludexol-CL use specifically for the elderly population?

Official product information advises caution in older adults due to the potential for increased sensitivity to the cardiovascular stimulant effects of the medicine.

Q: How is the use of Fludexol-CL described for patients who have pre-existing kidney problems?

Official guidelines state that individuals with documented severe renal impairment (kidney problems) may be considered for a dosage reduction or extended dosing interval. This consideration is made to prevent potential systemic accumulation.

Q: What is the reason people with certain heart conditions may not be eligible for Fludexol-CL?

Restrictions are based on the potential risk of exacerbating pre-existing heart conditions, such as rapid, irregular heartbeats, due to the drug's stimulant properties.

Q: Does the official labeling of Fludexol-CL include special considerations for people with diabetes?

Official labeling advises caution for individuals with uncontrolled diabetes mellitus due to the potential for a transient increase in blood sugar. This effect is temporary.

Q: Is Fludexol-CL officially associated with any risk of dependence or withdrawal symptoms?

According to the official regulatory label, Fludexol-CL is not associated with a known risk of dependence or withdrawal symptoms.

How should Fludexol-CL be stored and disposed of?

How to Store and Dispose of Fludexol-CL?

This section outlines the official regulatory requirements for storing, handling, and disposing of Fludexol-CL, based strictly on government-issued labeling.

Storage/Disposal Aspect Official Regulatory Requirement
Temperature & Environment Store at controlled room temperature, typically 20 C to 25 C.
Handling & Protection Keep in the original container. Protect from moisture and light. Do not freeze or expose to excessive heat.
Child Safety Must be kept out of the sight and reach of children.
Disposal The preferred method is a drug take-back location or a mail-back program. If these are unavailable, unused or expired medication should be mixed with an undesirable substance (e.g., used coffee grounds), placed in a sealed container, and thrown in the household trash.

These instructions define the mandatory conditions for maintaining the medicine's quality and ensuring safety. Disposal must follow authorized pharmaceutical-waste pathways or established government-recommended steps.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fludexol-CL found in:

A-Z Index: